

From: SANTE INFO
Sent: jeudi 24 juin 2021 17:55
To: SANTE CONSULT-C1
Cc: SANTE INFO
Subject: FW: New thereapeutics

Dear colleagues,

We have been asked a question via the spokesperson on the above. Full details can be found below.

Could you please provide us with a draft reply or reply directly (with SANTE INFO in copy) within 12 working days by 12 July as per the Code of Good Administrative Behaviour?

Many thanks in advance,

SANTE INFO

From: [REDACTED] <[REDACTED]@yahoo.com>
Sent: Wednesday, June 23, 2021 4:24 PM
To: [REDACTED] <[REDACTED]@ec.europa.eu>
Subject: New thereapeutics

Hi [REDACTED]

Hope all is well with you and your friends and family. We have all certainly suffered enough already.

So I am curious as to the progress of the new strategy proposed a few months ago by the European Commission for the rapid advancement of therapeutics for COVID.

Two questions I have in this regard that perhaps you can guide me for more information on the latest developments.

What therapeutics have been identified thus far?

Has Leronlimab by CytoDyn Corporation been adopted yet or on your candidate list for consideration?

What are the opinions on already existing therapies like HCL and Ivermectin? Are they considered also or in a separate category?

Best Regards, May we get through this together.

[REDACTED]

"We will do so by investing in research and innovation, the identification of new promising medicines, ramping up production capacity and supporting equitable access. Our Therapeutics Strategy is a strong European Health Union in action."

Commissioner for Innovation, Research, Culture, Education and Youth, Mariya Gabriel, said: *"By increasing vaccine availability across Europe, more and more Europeans are now protected against COVID-19. In the meantime, the development of innovative medicines to treat coronavirus patients remains a priority when it comes to saving lives. Research and innovation is the first step to finding effective and safe therapeutics, which is why we are proposing to establish a new COVID-19 'therapeutics innovation booster' and will invest € 90 million in population studies and clinical trials."*

Background

The Strategy on COVID-19 therapeutics complements the [EU strategy for COVID-19](#) vaccines from June 2020 and builds on ongoing work by the European Medicines Agency and the Commission to support research, development, manufacturing and deployment of therapeutics.

The Strategy forms part of a strong [European Health Union](#), using a coordinated EU approach to better protect the health of our citizens, equip the EU and its Member States to better prevent and address future pandemics, and improve the resilience of Europe's health systems."